IQWIG Finds No Added Benefit With Novo’s Xultophy Or Lundbeck’s Brintellix
This article was originally published in The Pink Sheet Daily
Executive Summary
The preliminary evaluation now goes to Germany’s Federal Joint Committee to make a final decision on the products’ usefulness in the country’s health care system, and their future pricing.